Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inflammatory Bowel Disease V: Surgical Management01:21

Inflammatory Bowel Disease V: Surgical Management

881
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
881
Inflammatory Bowel Disease II: Crohn's Disease01:30

Inflammatory Bowel Disease II: Crohn's Disease

1.6K
Introduction
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
1.6K
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

667
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
667
Drugs for Treatment of Diarrhea-Predominant IBS01:17

Drugs for Treatment of Diarrhea-Predominant IBS

924
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
924
Bacterial Flora of the Large Intestine01:29

Bacterial Flora of the Large Intestine

2.0K
The gut microbiome is formed by a vast and diverse community of bacteria that colonizes our large intestine. These bacteria start residing in the gut from birth and continue diversifying throughout life, influenced by factors such as diet, lifestyle, and stress. The gut bacterial community also includes bacteria from food and those that enter the colon through the anus.
The normal gut flora of the colon plays a critical role in generating essential vitamins such as vitamins K, B5, and B7.
2.0K
Chronic Bowel Disorders: Introduction01:17

Chronic Bowel Disorders: Introduction

950
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
950

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Implementation of a SARS-CoV-2 genomic surveillance network as a strategy to face other health challenges in Peru.

Revista peruana de medicina experimental y salud publica·2026
Same author

Genomic epidemiology of SARS-CoV-2 in Peru from 2020 to 2024.

Communications medicine·2026
Same author

Country-level assessment of infection prevention and control in public hospitals in Peru.

Infection, disease & health·2025
Same author

Disseminated <i>Lomentospora prolificans</i> infection in a neutropenic patient with acute monocytic leukemia: a clinical and diagnostic challenge.

ASM case reports·2025
Same author

Protection of Prior SARS-CoV-2 Infection Against Different Variants, Including Omicron Descendants, in a Country with High Viral Transmission.

Pathogens & immunity·2025
Same author

Metagenomic analysis reveals distinct patterns of gut microbiota features with diversified functions in <i>C. difficile</i> infection (CDI), asymptomatic carriage and non-CDI diarrhea.

Gut microbes·2025

Related Experiment Video

Updated: Apr 13, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.9K

Recurrent Clostridium difficile infection: From colonization to cure.

Kelsey Shields1, Roger V Araujo-Castillo2, Thimmaiah G Theethira1

  • 1Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave., Boston, MA 02215, United States.

Anaerobe
|May 2, 2015
PubMed
Summary

Recurrent Clostridium difficile infection (CDI) is rising, causing significant health and economic burdens. New therapies are urgently needed to effectively manage this challenging condition.

Keywords:
AntibioticFecal microbiota therapyInfection controlInfectious diarrheaNosocomial infectionToxin

More Related Videos

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

40.5K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.5K

Related Experiment Videos

Last Updated: Apr 13, 2026

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection
07:06

Fecal Microbiota Transplantation via Colonoscopy for Recurrent C. difficile Infection

Published on: December 8, 2014

27.9K
Culturing and Maintaining Clostridium difficile in an Anaerobic Environment
11:13

Culturing and Maintaining Clostridium difficile in an Anaerobic Environment

Published on: September 14, 2013

40.5K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.5K

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Gastroenterology

Background:

  • Clostridium difficile infection (CDI) incidence is increasing globally.
  • Recurrent CDI (RCDI) presents a significant challenge due to rising rates and lack of effective treatments.
  • RCDI leads to substantial morbidity, mortality, and economic costs.

Purpose of the Study:

  • To review the epidemiology, pathogenesis, and clinical presentation of RCDI.
  • To evaluate current management strategies for RCDI.
  • To explore novel and emerging therapeutic options for RCDI.

Main Methods:

  • Literature review of epidemiological data.
  • Analysis of pathogenesis factors contributing to recurrence.
  • Evaluation of existing and investigational treatment modalities.

Main Results:

  • RCDI incidence and associated burdens are escalating.
  • Current treatment options for RCDI lack uniform efficacy and consensus.
  • Data on RCDI-specific treatments remain limited.

Conclusions:

  • Effective and novel therapeutic strategies are essential for RCDI.
  • Further research is needed to identify and treat patients at risk for RCDI.
  • This review highlights the urgent need for improved RCDI management approaches.